IL2RA/CD25
Alpha Lifetech can provide IL2RA/CD25 corresponding products, help each customer's research and development.
01
Introduction To IL2RA/CD25
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to IL2RA/CD25 protein is a common target in medicine.
CD25 is the α -chain of the heterotrimeric IL-2 receptor, which is expressed at high levels in many types of hematological malignancies, but at low levels in most solid tumors. CD25 is also highly expressed in activated circulating immune cells and regulatory T cells (Tregs, CD25 molecule is encoded by the gene IL 2 RA, a single-stranded protein containing about 272 amino acid residues, including 21 amino acid residues signal peptide, a mature molecule containing 251 amino acids, multiple cysteines, and 2 N glycosylation sites. The extracellular region of CD25 contains a single Ig-like fold consisting of a type V (variable) region and a C-type (constant) region. This domain is characterized by having a specific binding site for binding to the IL-2 molecule.
Function of Target IL2RA/CD25
Studies in mice lacking IL-2 or its receptors show evidence of T cell immunodeficiency, suggesting that the role of CD25 is to mediate cellular immune responses. Loss of CD25 expression is associated with increased IL-2 production, increased cytotoxic T cell (CTL) function improved Th 1 differentiation, and concomitant upregulation to limit immune responses to autoantigens CD25 is now commonly used as one of several alternative biomarkers to identify regulatory T cells (Tregs) as its expression increases as the number of these inhibitory cytokine-secreting T cells increases. CD25 is one of the earliest T cell markers detectable on thymocytes before CD8 expression. Meanwhile, CD25 has also been proposed as an effector/memory CTL for antigen activation and a potential marker for senescent T cells.
Gene Pathway of Target IL2RA/CD25
CD25 is the only subunit that binds to IL-2, IL-2 is a cytokine with a low affinity, It is first bound to CD25 (IL-2R α), Forming a low-affinity complex, This binding promotes the formation of a heterodimer of IL-2R β and IL-2R γ, Thus forming a high-affinity IL-2R complex, Thus promoting the formation of the IL 2 R α / β / γ and IL-2 tetramers, Ultimately initiated the signal transduction, Mainly triggers three signaling pathways: JAK / STAT 5, PI3K / Akt / mTOR and MAPK, These signaling pathways play crucial roles in cell growth, survival, differentiation, and immune processes. CD25, as a potential therapeutic target, can enhance the immune response by regulating these signaling pathways, especially by affecting the function of regulatory T cells (Tregs). Tregs play an important role in maintaining immune homeostasis, but their hyperactivation may suppress antitumor immune responses in the tumor microenvironment. Therefore, depleting Tregs by targeting CD25 can restore the balance between effector T cells (Teffs) and Tregs, thus improving the efficiency of the antitumor immune response.
Fig 1: CD25 Gene Pathway. (Reference source: Wu JH, Zhou M, Jin Y, et al,. Generation and Immune Regulation of CD4+CD25-Foxp3+ T Cells in Chronic Obstructive Pulmonary Disease. Front Immunol. 2019 Feb 20;10:220.)
Alpha Lifetech Can Provide
Currently, various immune drugs targeting IL2RA/CD25 targets are in the updating iteration, and taking the disease alone or in combination with other products has become a new approach with remarkable achievements. The IL2RA/CD25 targets have shown important research value and application prospects in both biology and drug research and development. With further research and detection technology advances, IL2RA/CD25 target products are also essential in medical research.Alpha Lifetech can provide IL2RA/CD25 corresponding products and help each customer's research and development. In addition, Alpha Lifetech also provides advanced expression systems and purification services to accelerate antibody research and development. Our synthesized antibody expression undergoes rigorous quality validation, including sequencing validation and functional expression analysis, to ensure high fidelity and performance. In addition, Alpha Lifetech provides customized solutions for recombinant proteins, such as codon optimization, promoter selection, and vector design, supplemented by downstream applications such as protein expression analysis to meet specific experimental needs.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ADT1158 | 1mg,5mg | |
| ADT1319 | ADT1319-Inolimomab Biosimilar-Anti IL2RA mAb- Research Grade | 1mg,5mg |
| ADT1070 | ADT1070-Basiliximab Biosimilar-Anti IL2RA/CD25 mAb- Research Grade | 100ug,1mg,5mg |
| ADT1111 | ADT1111-Camidanlumab Biosimilar-Anti IL2RA/CD25 mAb- Research Grade | 100ug,1mg,5mg |
Reference
[1] Peng Y, Tao Y, Zhang Y, Wang J, Yang J, Wang Y. CD25: A potential tumor therapeutic target. Int J Cancer. 2023 Apr 1;152(7):1290-1303.
[2] Luo H, Zhu Y, Guo B, Ruan Z, Liu Z, Fan Z, Zhao S. Causal relationships between CD25 on immune cells and hip osteoarthritis. Front Immunol. 2023 Sep 4;14:1247710.
[3] Wang YX, Gu ZW, Cao ZW. Difference between CD25+Tregs and Helios+Tregs in a murine model of allergic rhinitis. Braz J Otorhinolaryngol. 2021 Sep-Oct;87(5):550-556.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102